Dong Fang Liu
Chief Tech/Sci/R&D Officer bij NUVATION BIO INC.
Vermogen: 21 840 $ op 31-03-2024
Profiel
Dong Fang Liu is currently the Chief Medical Officer at Nuvation Bio, Inc. Prior to this, he held positions as the Group Director-Oncology Clinical Research at Bristol Myers Squibb Co. and as the Executive Director at Celgene Corp.
From 2019 to 2021, he served as the Chief Medical Officer at 3D Medicines, Inc. Dr. Liu obtained a doctorate degree from the Massachusetts Institute of Technology in 2001.
He also holds a graduate degree from the University of Toledo (Ohio) conferred in 1997 and an undergraduate degree from Beijing Medical University received in 1993.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 29-02-2024 | 6 000 ( 0.00% ) | 21 840 $ | 31-03-2024 |
Actieve functies van Dong Fang Liu
| Bedrijven | Functie | Begin |
|---|---|---|
| NUVATION BIO INC. | Chief Tech/Sci/R&D Officer | 18-07-2022 |
Eerdere bekende functies van Dong Fang Liu
| Bedrijven | Functie | Einde |
|---|---|---|
| 3D MEDICINES INC. | Chief Tech/Sci/R&D Officer | 01-03-2021 |
| CELGENE | Director/Board Member | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Opleiding van Dong Fang Liu
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Toledo (Ohio) | Graduate Degree |
| Beijing Medical University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| NUVATION BIO INC. | Health Technology |
| 3D MEDICINES INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
